Everything below concerns heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
At least eighteen people were killed and at least 78 others were injured in a Russian missile attack on Chernihiv. Ukraine claimed responsibility for an attack at the Dzhankoi air base in Crimea, during which six explosions were reported. Russian milbloggers and Ukrainian sources said that ATACMS missiles or ballistic missiles were used, some of which deployed cluster munitions. A milbloggers claimed 30 people were killed and 80 others wounded. Ukraine said four missile launchers were 'critically damaged' in the attack. Subsequent satellite pictures showed the destruction of between three and five S-300 or S-400 systems and other areas marked with "scorch marks" that suggested equipment that had been damaged but removed. Ukrainian media reported that the HUR struck a radar system in the Russian republic of Mordovia and a factory producing bomber aircraft in Tatarstan using drones. The Canadian government announced that it would budget some 1.6 billion Canadian dollars ($1.16 billion) in military aid for Ukraine over the next five years.
== Proteomics in cancer and tumor microenvironment == In addition, proteomic approaches are very useful in characterizing tumor microenvironments, which show how populations of cells influence cancer progression through protein interactions. Proteomics is especially well suited to the analysis of the microenvironment, considering that the origin of many components of the microenvironment is host tissue, with no appreciable genomic alteration detectable, and that the release and shedding of proteins from the surface of cancer cells contribute significantly, all of which cannot be predicted strictly from genomic analysis. It especially helped advance proteomic analysis toward a better understanding of how tumor cells manipulate their microenvironment by producing structural proteins of ECM, modifying proteins of ECM, and proteases. Proteomics has also further advanced the global identification of protease targets.
Mostly in the 1990s, several books were published that were critical of cold fusion research methods and the conduct of cold fusion researchers. Over the years, several books have appeared that defended them. Around 1998, the University of Utah had already dropped its research after spending over $1 million, and in the summer of 1997, Japan cut off research and closed its own lab after spending $20 million.
=== Patenting === In the U.S., efforts into creating a chimeric entity appeared to be legal when the topic first came up. Developmental biologist Stuart Newman, a professor at New York Medical College in Valhalla, N.Y., applied for a patent on a human-animal chimera in 1997 as a challenge to the U.S. Patent and Trademark Office and the U.S. Congress, motivated by his moral and scientific opposition to the notion that living things can be patented at all. Prior legal precedent had established that genetically engineered entities, in general, could be patented, even if they were based on beings occurring in nature. After a seven-year process, Newman's patent finally received a flat rejection. The legal process had created a paper trail of arguments, giving Newman what he claimed was a victory. The Washington Post ran an article on the controversy that stated that it had raised "profound questions about the differences—and similarities—between humans and other animals, and the limits of treating animals as property."
Sources: en.wikipedia.org
Amino acids are polymerised via peptide bonds to form a long backbone, with the different amino acid side chains protruding along it. In biological systems, proteins are produced during translation by a cell's ribosomes. Some organisms can also make short peptides by non-ribosomal peptide synthesis, which often use amino acids other than the encoded 22, and may be cyclised, modified and cross-linked.
== Research == Sertraline may be useful to treat murine Zaire ebolavirus (murine EBOV). The World Health Organization (WHO) considers this a promising area of research. Lass-Flörl et al., 2003 finds it significantly inhibits phospholipase B in the fungal genus Candida, reducing virulence. Sertraline is also an effective leishmanicide. Specifically, Palit & Ali 2008 find that sertraline kills almost all promastigotes of Leishmania donovani. Sertraline is strongly antibacterial against some species. It is also known to act as a photosensitizer of bacterial surfaces. In combination with antibacterials its photosensitization effect reverses antibacterial resistance. As such sertraline shows promise for food preservation. Lass-Flörl et al., 2003 finds this compound acts as a fungicide against Candida parapsilosis. Its anti-Cp effect is indeed due to its serotonergic activity and not its other effects. Sertraline is a promising trypanocide. It acts at several different life stages and against several strains. Sertraline's trypanocidal mechanism of action is by way of interference with bioenergetics. When mothers take sertraline during pregnancy, there is research evidence that the newborn may experience sertraline withdrawal symptoms.
== History == 1919 F.D. Edwards establishes Edwards Equipment and Services in London, England. 1939 F.D. Edwards begins manufacturing vacuum equipment. 1955 The company acquires Alto Vuoto SpA, a freeze drying manufacturer in Italy. 1968 The company is acquired by BOC, after staying in private hands through the post-war period and until the 1960s when it went public. 1977 BOC Edwards acquire Kniese Apparatbau GmbH, a freeze drying manufacturer in Germany. 1992 Restructuring of Freeze Drying business resource centralised in Tonawanda (US). 1994 The company’s product portfolio is expanded with the acquisition of pharmaceutical filling systems from Calumatic in The Netherlands. 1995 The company’s portfolio is further expanded with loading systems introduced from the Dongen manufacturing site in The Netherlands. 2004 A joint venture is established with Tianli Cryogenic Company, a pharmaceutical freeze dryer manufacturer in Beijing, China. 2006 The BOC Group is acquired by Linde AG and together form The Linde Group. Linde sells the vacuum division of BOC Edwards. BOC Edwards Pharmaceutical Systems remains part of the Linde Group, as an independent division. 2008 IMA, Italy acquires the BOC Edwards Pharmaceutical Systems group creating IMA Edwards – a part of IMA Life division of the IMA group. 2010 Today the whole group has been renamed under the brand IMA LIFE - Aseptic Processing and Freeze Drying Solutions.
Sources: en.wikipedia.org
oligo dT A short, single-stranded DNA oligonucleotide consisting of a sequence of repeating deoxythymidine (dT) nucleotides. Oligo dTs are commonly synthesized de novo to be used as primers for in vitro reverse transcription reactions during rtPCR techniques, where short chains of 12 to 18 thymine bases readily complement the poly(A) tails of mature messenger RNAs, allowing the selective amplification and preparation of a cDNA library from a pool of coding transcripts.
Initially, Zverev had difficulty adjusting to this training style on the court, saying, "I had no idea what was going on in my body", and needed to adapt his shot technique as he became more muscular. Eventually, he improved on the court. Green remarked, "He started to become less wobbly. He started to absorb the power, so when someone hit hard he could hit the ball back and everything locked into place."
Ancrod (also known as Viprinex), a serine protease derived from the venom of the Malayan pit vipers, was under development for the treatment of acute ischemic stroke; after Knoll was acquired by Abbott, Abbott licensed the rights to ancrod to Empire Pharmaceuticals, a startup that included a Knoll employee who had worked on ancrod. In 2004 Empire was acquired by Neurobiological Technologies (NTI). Ancrod failed in a Phase III clinical trial in 2008, which led to the demise of NTI.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.